Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
LTR Pharma Limited ( (AU:LTP) ) has provided an update.
LTR Pharma Limited announced the release of 69,014,764 fully paid ordinary shares and 4,792,344 options from ASX mandatory escrow on December 11, 2025. This release marks a significant step for the company as it prepares to apply for quotation of these shares, potentially enhancing liquidity and shareholder value. Executive Chairman Lee Rodne, who holds a substantial interest in the released shares, underscores the alignment of interests with shareholders. The move is expected to impact the company’s operations positively by increasing market participation and potentially strengthening its industry positioning.
More about LTR Pharma Limited
LTR Pharma is a commercial-stage pharmaceutical company focused on delivering innovative therapies for unmet medical needs through its proprietary intranasal drug delivery platform. The company has commercialized rapid-acting treatment technology in Australia and is expanding access while advancing regulatory pathways in the US and other key markets. Its lead products include SPONTAN® and ROXUS®, which are fast-acting intranasal sprays for erectile dysfunction, and OROFLOW®, a novel spray under development for Oesophageal Motility Disorders.
Average Trading Volume: 608,412
Technical Sentiment Signal: Sell
Current Market Cap: A$85.37M
Learn more about LTP stock on TipRanks’ Stock Analysis page.